Evidence map›Paper›PMID 25889802›Full record

ArticleMicrobial cell factories2015

Systematic comparison of single-chain Fv antibody-fusion toxin constructs containing Pseudomonas Exotoxin A or saporin produced in different microbial expression systems.

Pietro Della Cristina, Monica Castagna, Alessio Lombardi, Erika Barison, Giovanni Tagliabue, Aldo Ceriotti, Ilias Koutris, Luana Di Leandro, Francesco Giansanti, Riccardo Vago and 5 more

Open access · goldAbstract readComparative Study
In one paragraph

Article in Microbial cell factories, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 27 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Antibody-Drug Conjugates: The New Frontier of Chemotherapy.International journal of molecular sciences · 2020
    Review
  12. Article
  13. Review
  14. Review
  15. Antiviral Immunotoxin AgainstFrontiers in microbiology · 2018
    Article
  16. Article
  17. Review
  18. Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 2 countries.

Pietro Della CristinaDepartment of Pathology and Diagnostics, University of Verona, Verona, Italy. pietro.decri@gmail.com.
Monica CastagnaDepartment of Pathology and Diagnostics, University of Verona, Verona, Italy. monica.castagna@univr.it.
Alessio LombardiIstituto Biologia e Biotecnologia Agraria, CNR, Milan, Italy. alessiolombardi64@yahoo.it.
Erika BarisonDepartment of Pathology and Diagnostics, University of Verona, Verona, Italy. erika.barison@gmail.com.
Giovanni TagliabueIstituto Biologia e Biotecnologia Agraria, CNR, Milan, Italy. giovannitagliabue@virgilio.it.
Aldo CeriottiIstituto Biologia e Biotecnologia Agraria, CNR, Milan, Italy. ceriotti@ibba.cnr.it.
Ilias KoutrisDepartment of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy. ikoutris@yahoo.com.
Luana Di LeandroDepartment of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy. luana.dileandro@univaq.it.
Francesco GiansantiDepartment of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy. francesco.giansanti@cc.univaq.it.
Riccardo VagoDepartment of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy. vago.riccardo@hsr.it.
Rodolfo IppolitiDepartment of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy. rodolfo.ippoliti@univaq.it.
Sopsamorn U FlavellThe Simon Flavell Leukaemia Research Laboratory, (Leukaemia Busters), Southampton General Hospital, Southampton, UK. beef@leukaemiabusters.org.uk.
David J FlavellThe Simon Flavell Leukaemia Research Laboratory, (Leukaemia Busters), Southampton General Hospital, Southampton, UK. DavidF@leukaemiabusters.org.uk.
Marco ColombattiDepartment of Pathology and Diagnostics, University of Verona, Verona, Italy. marco.colombatti@univr.it.
Maria Serena FabbriniIstituto Biologia e Biotecnologia Agraria, CNR, Milan, Italy. msfabbrini@gmail.com.
University of L'Aquila · ITIstituto di Biologia e Biotecnologia Agraria · ITUniversity of Verona · ITBlood Cancer UK · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAntibodies raised against selected antigens over-expressed at the cell surface of malignant cells have been chemically conjugated to protein toxin domains to obtain immunotoxins (ITs) able to selectively kill cancer cells. Since latest generation immunotoxins are composed of a toxic domain genetically fused to antibody fragment(s) which confer on the IT target selective specificity, we rescued from the hydridoma 4KB128, a recombinant single-chain variable fragment (scFv) targeting CD22, a marker antigen expressed by B-lineage leukaemias and lymphomas. We constructed several ITs using two enzymatic toxins both able to block protein translation, one of bacterial origin (a truncated version of Pseudomonas exotoxin A, PE40) endowed with EF-2 ADP-ribosylation activity, the other being the plant ribosome-inactivating protein saporin, able to specifically depurinate 23/26/28S ribosomal RNA. PE40 was selected because it has been widely used for the construction of recombinant ITs that have already undergone evaluation in clinical trials. Saporin has also been evaluated clinically and has recently been expressed successfully at high levels in a Pichia pastoris expression system. The aim of the present study was to evaluate optimal microbial expression of various IT formats.

resultsAn anti-CD22 scFv termed 4KB was obtained which showed the expected binding activity which was also internalized by CD22+ target cells and was also competed for by the parental monoclonal CD22 antibody. Several fusion constructs were designed and expressed either in E. coli or in Pichia pastoris and the resulting fusion proteins affinity-purified. Protein synthesis inhibition assays were performed on CD22+ human Daudi cells and showed that the selected ITs were active, having IC50 values (concentration inhibiting protein synthesis by 50% relative to controls) in the nanomolar range.

conclusionsWe undertook a systematic comparison between the performance of the different fusion constructs, with respect to yields in E. coli or P. pastoris expression systems and also with regard to each constructs specific killing efficacy. Our results confirm that E. coli is the system of choice for the expression of recombinant fusion toxins of bacterial origin whereas we further demonstrate that saporin-based ITs are best expressed and recovered from P. pastoris cultures after yeast codon-usage optimization.

Indexed as

ADP Ribose TransferasesBacterial ToxinsBlotting, WesternBurkitt LymphomaCell LineCell Line, TumorCell SurvivalDose-Response Relationship, DrugEscherichia coliExotoxinsHumansImmunotoxinsPichiaProtein BiosynthesisPseudomonas aeruginosa Exotoxin ARecombinant Fusion ProteinsADP Ribose TransferasesBacterial ToxinsExotoxinsImmunotoxinsPseudomonas aeruginosa Exotoxin ARecombinant Fusion ProteinsRibosome Inactivating Proteins, Type 1SaporinsSialic Acid Binding Ig-like Lectin 2Single-Chain AntibodiesVirulence Factors

Identifiers

PMID25889802
PMCPMC4338634
OpenAlexW2132646736

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.